Semaglutide is the FDA-approved GLP-1 receptor agonist behind Ozempic and Wegovy, with 94% amino-acid homology to native GLP-1. It quiets hunger through hypothalamic satiety centres and slows gastric emptying. What keeps researchers watching is how fast the label is widening: chronic kidney disease in January 2025, MASH with F2-F3 fibrosis in August 2025.
- FDA-approved GLP-1 receptor agonist with 94% amino-acid homology to native GLP-1, acting through hypothalamic satiety centres plus delayed gastric emptying.Peptide Guide p. 89
- The FLOW trial earned it an FDA indication in chronic kidney disease in January 2025.FDA indications (FLOW, Jan 2025)
- Wegovy added MASH with F2-F3 fibrosis in August 2025, on top of type-2 diabetes glycemic control and cardiovascular-risk reduction in established CVD.FDA indications (Aug 2025)
- In published sex-difference research, women lose more weight than men at the same dose while reporting more GI effects.GLP-1 sex differences (PubMed)
- In men, GLP-1 exposure raises total testosterone, SHBG and gonadotropins as weight drops, improves sperm and erectile function, and preserves fertility, unlike TRT.Jensterle 2020